Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Blesl

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Scientific Reports|February 19, 2020
The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot studyAngela Horvath, Bettina Leber, Nicole Feldbacher, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 17, 2020
Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosisVanessa Stadlbauer, Irina Komarova, Ingeborg Klymiuk, et al.
Scandinavian Journal of Gastroenterology|June 22, 2022
Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective studyAndreas Blesl, Wolfgang Petritsch, Lukas Binder, et al.
Digestive Diseases and Sciences|September 19, 2024
Acquired Low Factor XIII Activity Is Associated with an Increased Need for Blood Transfusions in Patients with Gastrointestinal BleedingsAnna Traninger, Andreas Blesl, Andrea Borenich, et al.
European Journal of Nutrition|November 16, 2019
Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot studyAngela Horvath, Bettina Leber, Nicole Feldbacher, et al.
Digestive Diseases and Sciences|December 23, 2019
Successful Pregnancies After Regression of AA Amyloidosis by Anti-inflammatory Therapy in Chronic Active Crohn's DiseaseAndreas Blesl, Florian Rainer, Marion Pollheimer, et al.
Inflammatory Bowel Diseases|April 29, 2025
The Fecal Microbiome of IBD Patients Is Less Divertible by Bowel Preparation Compared to Healthy Controls: Results From a Prospective StudyAndreas Blesl, Lukas Binder, Bettina Halwachs, et al.
Alimentary Pharmacology & Therapeutics|June 21, 2021
Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world studyAndreas Blesl, Lukas Binder, Christoph Högenauer, et al.
Biomed Research International|May 22, 2026
Anti-TNF Drug-Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature ReviewPatrick Bez, Zlata Chkolnaia, Annalisa Aratari, et al.
Nutrients|September 10, 2020
Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control StudyAndreas Blesl, Christoph Jüngst, Frank Lammert, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Scientific Reports|February 19, 2020
The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot studyAngela Horvath, Bettina Leber, Nicole Feldbacher, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 17, 2020
Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosisVanessa Stadlbauer, Irina Komarova, Ingeborg Klymiuk, et al.
Scandinavian Journal of Gastroenterology|June 22, 2022
Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective studyAndreas Blesl, Wolfgang Petritsch, Lukas Binder, et al.
Digestive Diseases and Sciences|September 19, 2024
Acquired Low Factor XIII Activity Is Associated with an Increased Need for Blood Transfusions in Patients with Gastrointestinal BleedingsAnna Traninger, Andreas Blesl, Andrea Borenich, et al.
European Journal of Nutrition|November 16, 2019
Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot studyAngela Horvath, Bettina Leber, Nicole Feldbacher, et al.
Digestive Diseases and Sciences|December 23, 2019
Successful Pregnancies After Regression of AA Amyloidosis by Anti-inflammatory Therapy in Chronic Active Crohn's DiseaseAndreas Blesl, Florian Rainer, Marion Pollheimer, et al.
Inflammatory Bowel Diseases|April 29, 2025
The Fecal Microbiome of IBD Patients Is Less Divertible by Bowel Preparation Compared to Healthy Controls: Results From a Prospective StudyAndreas Blesl, Lukas Binder, Bettina Halwachs, et al.
Alimentary Pharmacology & Therapeutics|June 21, 2021
Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world studyAndreas Blesl, Lukas Binder, Christoph Högenauer, et al.
Biomed Research International|May 22, 2026
Anti-TNF Drug-Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature ReviewPatrick Bez, Zlata Chkolnaia, Annalisa Aratari, et al.
Nutrients|September 10, 2020
Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control StudyAndreas Blesl, Christoph Jüngst, Frank Lammert, et al.
Pageof 4